{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T19:33:04Z","timestamp":1767987184265,"version":"3.49.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,10,10]],"date-time":"2018-10-10T00:00:00Z","timestamp":1539129600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Heuer Stiftung"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Gynecol Obstet"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1007\/s00404-018-4928-9","type":"journal-article","created":{"date-parts":[[2018,10,10]],"date-time":"2018-10-10T10:26:39Z","timestamp":1539167199000},"page":"203-209","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Glucocorticoid receptor in cervical cancer: an immunhistochemical analysis"],"prefix":"10.1007","volume":"299","author":[{"given":"Bernd Peter","family":"Kost","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susanne","family":"Beyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lennard","family":"Schr\u00f6der","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junyan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Doris","family":"Mayr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"Kuhn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Schulze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simone","family":"Hofmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sven","family":"Mahner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2623-3235","authenticated-orcid":false,"given":"Udo","family":"Jeschke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helene","family":"Heidegger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,10,10]]},"reference":[{"key":"4928_CR1","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1002\/ijc.20244","volume":"111","author":"N Munoz","year":"2004","unstructured":"Munoz N, Bosch FX, Castellsague X, Diaz M, de Sanjose S, Hammouda D, Shah KV, Meijer CJ (2004) Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 111:278\u2013285","journal-title":"Int J Cancer"},{"key":"4928_CR2","doi-asserted-by":"publisher","first-page":"8749","DOI":"10.7314\/APJCP.2014.15.20.8749","volume":"15","author":"A Serrano-Olvera","year":"2014","unstructured":"Serrano-Olvera A, Cetina L, Coronel J, Duenas-Gonzalez A (2014) Follow-up consultations for cervical cancer patients in a mexican cancer center. Comparison with NCCN guidelines. Asian Pac J Cancer Prev 15:8749\u20138752","journal-title":"Asian Pac J Cancer Prev"},{"key":"4928_CR3","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s00292-015-0114-z","volume":"36","author":"LC Horn","year":"2015","unstructured":"Horn LC, Beckmann MW, Follmann M, Koch MC, Mallmann P, Marnitz S, Schmidt D, German Cancer S (2015) s3 guidelines on diagnostics and treatment of cervical cancer: demands on pathology. Pathologe 36:585\u2013593","journal-title":"Pathologe"},{"key":"4928_CR4","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/S0140-6736(07)61416-0","volume":"370","author":"M Schiffman","year":"2007","unstructured":"Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S (2007) Human papillomavirus and cervical cancer. Lancet 370:890\u2013907","journal-title":"Lancet"},{"issue":"Suppl 1","key":"4928_CR5","first-page":"S1","volume":"91","author":"C Wittekindt","year":"2012","unstructured":"Wittekindt C, Wagner S, Mayer CS, Klussmann JP (2012) basics of tumor development and importance of human papilloma virus (HPV) for head and neck cancer. Laryngorhinootologie 91(Suppl 1):S1\u2013S26","journal-title":"Laryngorhinootologie"},{"key":"4928_CR6","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1056\/NEJMoa021641","volume":"348","author":"N Munoz","year":"2003","unstructured":"Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders PJ, Meijer CJ, International Agency for Research on Cancer Multicenter Cervical Cancer Study G (2003) Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348:518\u2013527","journal-title":"N Engl J Med"},{"key":"4928_CR7","doi-asserted-by":"publisher","first-page":"461","DOI":"10.3109\/09513590.2014.898054","volume":"30","author":"J Liu","year":"2014","unstructured":"Liu J, Cheng Y, He M, Yao S (2014) Vascular endothelial growth factor c enhances cervical cancer cell invasiveness via upregulation of galectin-3 protein. Gynecol Endocrinol 30:461\u2013465","journal-title":"Gynecol Endocrinol"},{"key":"4928_CR8","first-page":"1273","volume":"4","author":"CF Meng","year":"2011","unstructured":"Meng CF, Su B, Li W (2011) DNA demethylation is superior to histone acetylation for reactivating cancer-associated genes in ovarian cancer cells. Mol Med Rep 4:1273\u20131278","journal-title":"Mol Med Rep"},{"key":"4928_CR9","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.virol.2003.08.008","volume":"317","author":"S Gupta","year":"2003","unstructured":"Gupta S, Takhar PP, Degenkolbe R, Koh CH, Zimmermann H, Yang CM, Guan Sim K, Hsu SI, Bernard HU (2003) The human papillomavirus type 11 and 16 e6 proteins modulate the cell-cycle regulator and transcription cofactor trip-br1. Virology 317:155\u2013164","journal-title":"Virology"},{"key":"4928_CR10","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/0092-8674(93)90384-3","volume":"75","author":"M Scheffner","year":"1993","unstructured":"Scheffner M, Huibregtse JM, Vierstra RD, Howley PM (1993) The hpv-16 e6 and e6-ap complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 75:495\u2013505","journal-title":"Cell"},{"key":"4928_CR11","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/1743-422X-7-123","volume":"7","author":"D Pittayakhajonwut","year":"2010","unstructured":"Pittayakhajonwut D, Angeletti PC (2010) Viral trans-factor independent replication of human papillomavirus genomes. Virol J 7:123","journal-title":"Virol J"},{"key":"4928_CR12","doi-asserted-by":"publisher","first-page":"9702","DOI":"10.1128\/JVI.76.19.9702-9715.2002","volume":"76","author":"JL Bromberg-White","year":"2002","unstructured":"Bromberg-White JL, Meyers C (2002) The upstream regulatory region of human papillomavirus type 31 is insensitive to glucocorticoid induction. J Virol 76:9702\u20139715","journal-title":"J Virol"},{"key":"4928_CR13","doi-asserted-by":"crossref","first-page":"3261","DOI":"10.1128\/JVI.63.8.3261-3269.1989","volume":"63","author":"WK Chan","year":"1989","unstructured":"Chan WK, Klock G, Bernard HU (1989) Progesterone and glucocorticoid response elements occur in the long control regions of several human papillomaviruses involved in anogenital neoplasia. J Virol 63:3261\u20133269","journal-title":"J Virol"},{"key":"4928_CR14","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1099\/0022-1317-82-1-201","volume":"82","author":"K Webster","year":"2001","unstructured":"Webster K, Taylor A, Gaston K (2001) Oestrogen and progesterone increase the levels of apoptosis induced by the human papillomavirus type 16 e2 and e7 proteins. J Gen Virol 82:201\u2013213","journal-title":"J Gen Virol"},{"key":"4928_CR15","first-page":"153","volume":"26","author":"A Kwasniewska","year":"2011","unstructured":"Kwasniewska A, Postawski K, Gozdzicka-Jozefiak A, Kwasniewski W, Grywalska E, Zdunek M, Korobowicz E (2011) Estrogen and progesterone receptor expression in HPV-positive and HPV-negative cervical carcinomas. Oncol Rep 26:153\u2013160","journal-title":"Oncol Rep"},{"key":"4928_CR16","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1136\/ijgc-00009577-200409000-00026","volume":"14","author":"JA Fonseca-Moutinho","year":"2004","unstructured":"Fonseca-Moutinho JA, Cruz E, Carvalho L, Prazeres HJ, de Lacerda MM, da Silva DP, Mota F, de Oliveira CF (2004) Estrogen receptor, progesterone receptor, and BCL-2 are markers with prognostic significance in cin iii. Int J Gynecol Cancer 14:911\u2013920","journal-title":"Int J Gynecol Cancer"},{"key":"4928_CR17","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1006\/bbrc.1996.1080","volume":"224","author":"YH Chen","year":"1996","unstructured":"Chen YH, Huang LH, Chen TM (1996) Differential effects of progestins and estrogens on long control regions of human papillomavirus types 16 and 18. Biochem Biophys Res Commun 224:651\u2013659","journal-title":"Biochem Biophys Res Commun"},{"key":"4928_CR18","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1530\/JOE-11-0135","volume":"211","author":"G Schlossmacher","year":"2011","unstructured":"Schlossmacher G, Stevens A, White A (2011) Glucocorticoid receptor-mediated apoptosis: mechanisms of resistance in cancer cells. J Endocrinol 211:17\u201325","journal-title":"J Endocrinol"},{"key":"4928_CR19","doi-asserted-by":"publisher","first-page":"65","DOI":"10.2147\/CMAR.S124475","volume":"9","author":"TS Block","year":"2017","unstructured":"Block TS, Murphy TI, Munster PN, Nguyen DP, Lynch FJ (2017) Glucocorticoid receptor expression in 20 solid tumor types using immunohistochemistry assay. Cancer Manag Res 9:65\u201372. https:\/\/doi.org\/10.2147\/CMAR.S124475","journal-title":"Cancer Manag Res"},{"key":"4928_CR20","doi-asserted-by":"publisher","first-page":"4467","DOI":"10.3892\/ol.2017.6752","volume":"14","author":"A Stiasny","year":"2017","unstructured":"Stiasny A, Freier CP, Kuhn C, Schulze S, Mayr D, Alexiou C, Janko C, Wiest I, Dannecker C, Jeschke U et al (2017) The involvement of e6, p53, p16, mdm2 and gal-3 in the clinical outcome of patients with cervical cancer. Oncol Lett 14:4467\u20134476","journal-title":"Oncol Lett"},{"key":"4928_CR21","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s00432-017-2510-7","volume":"144","author":"K Friese","year":"2018","unstructured":"Friese K, Kost B, Vattai A, Marme F, Kuhn C, Mahner S, Dannecker C, Jeschke U, Heublein S (2018) The g protein-coupled estrogen receptor (gper\/gpr30) may serve as a prognostic marker in early-stage cervical cancer. J Cancer Res Clin Oncol 144:13\u201319","journal-title":"J Cancer Res Clin Oncol"},{"key":"4928_CR22","doi-asserted-by":"publisher","first-page":"105356","DOI":"10.18632\/oncotarget.22187","volume":"8","author":"A Vattai","year":"2017","unstructured":"Vattai A, Cavailles V, Sixou S, Beyer S, Kuhn C, Peryanova M, Heidegger H, Hermelink K, Mayr D, Mahner S et al (2017) Investigation of rip140 and lcor as independent markers for poor prognosis in cervical cancer. Oncotarget 8:105356\u2013105371","journal-title":"Oncotarget"},{"key":"4928_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18030477","author":"S Beyer","year":"2017","unstructured":"Beyer S, Zhu J, Mayr D, Kuhn C, Schulze S, Hofmann S, Dannecker C, Jeschke U, Kost BP (2017) Histone h3 acetyl k9 and histone h3 tri methyl k4 as prognostic markers for patients with cervical cancer. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms18030477","journal-title":"Int J Mol Sci"},{"key":"4928_CR24","doi-asserted-by":"publisher","first-page":"iv72","DOI":"10.1093\/annonc\/mdx220","volume":"28","author":"C Marth","year":"2017","unstructured":"Marth C, Landoni F, Mahner S, McCormack M, Gonzalez-Martin A, Colombo N, Committee E G (2017) Cervical cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 28:iv72\u2013iv83","journal-title":"Ann Oncol"},{"key":"4928_CR25","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1055\/s-0035-1558052","volume":"75","author":"O Reich","year":"2015","unstructured":"Reich O, Regauer S, Marth C, Schmidt D, Horn LC, Dannecker C, Menton M, Beckmann MW (2015) Precancerous lesions of the cervix, vulva and vagina according to the 2014 who classification of tumors of the female genital tract. Geburtshilfe Frauenheilkd 75:1018\u20131020","journal-title":"Geburtshilfe Frauenheilkd"},{"key":"4928_CR26","first-page":"3131","volume":"36","author":"CP Freier","year":"2016","unstructured":"Freier CP, Stiasny A, Kuhn C, Mayr D, Alexiou C, Janko C, Wiest I, Jeschke U, Kost B (2016) Immunohistochemical evaluation of the role of p53 mutation in cervical cancer: Ser-20 p53-mutant correlates with better prognosis. Anticancer Res 36:3131\u20133137","journal-title":"Anticancer Res"},{"key":"4928_CR27","first-page":"3195","volume":"36","author":"A Stiasny","year":"2016","unstructured":"Stiasny A, Kuhn C, Mayr D, Alexiou C, Janko C, Wiest I, Jeschke U, Kost B (2016) Immunohistochemical evaluation of e6\/e7 hpv oncoproteins staining in cervical cancer. Anticancer Res 36:3195\u20133198","journal-title":"Anticancer Res"},{"key":"4928_CR28","doi-asserted-by":"publisher","first-page":"145","DOI":"10.2217\/fon-2016-0259","volume":"13","author":"TM Kolben","year":"2017","unstructured":"Kolben TM, Kraft F, Kolben T, Goess C, Semmlinger A, Dannecker C, Schmoeckel E, Mayr D, Sommer NN, Mahner S et al (2017) Expression of sialyl lewis a, sialyl lewis x, lewis y, gal-3, gal-7, stmn1 and p16 in cervical dysplasia. Future Oncol 13:145\u2013157","journal-title":"Future Oncol"},{"key":"4928_CR29","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1210\/mend-1-1-68","volume":"1","author":"JN Vanderbilt","year":"1987","unstructured":"Vanderbilt JN, Miesfeld R, Maler BA, Yamamoto KR (1987) Intracellular receptor concentration limits glucocorticoid-dependent enhancer activity. Mol Endocrinol 1:68\u201374","journal-title":"Mol Endocrinol"},{"key":"4928_CR30","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/0303-7207(84)90089-3","volume":"36","author":"U Gehring","year":"1984","unstructured":"Gehring U, Mugele K, Ulrich J (1984) Cellular receptor levels and glucocorticoid responsiveness of lymphoma cells. Mol Cell Endocrinol 36:107\u2013113","journal-title":"Mol Cell Endocrinol"},{"key":"4928_CR31","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/400_2008_20","volume":"49","author":"I Herr","year":"2009","unstructured":"Herr I, Buchler MW, Mattern J (2009) Glucocorticoid-mediated apoptosis resistance of solid tumors. Results Probl Cell Differ 49:191\u2013218","journal-title":"Results Probl Cell Differ"},{"issue":"6","key":"4928_CR32","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1016\/j.cell.2013.11.012","volume":"155","author":"Vivek K Arora","year":"2013","unstructured":"Arora Vivek K, Schenkein Emily, Murali Rajmohan et al (2013) Glucocorticoid receptor confers resistance to anti-androgens by bypassing androgen receptor blockade. Cell 155(6):1309\u20131322","journal-title":"Cell"},{"issue":"4","key":"4928_CR33","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1002\/cpdd.389","volume":"7","author":"H Hunt","year":"2017","unstructured":"Hunt H, Donaldson K, Strem M, Zann V, Leung P, Sweet S, Connor A, Combs D, Belanoff J (2017) Assessment of safety, tolerability, pharmacokinetics, and pharmacological effect of orally administered cort125134: An adaptive, double-blind, randomized, placebo-controlled phase 1 clinical study. Clin Pharmacol Drug Dev 7(4):408\u2013421. https:\/\/doi.org\/10.1002\/cpdd.389","journal-title":"Clin Pharmacol Drug Dev"},{"key":"4928_CR34","doi-asserted-by":"publisher","first-page":"3405","DOI":"10.1021\/acs.jmedchem.7b00162","volume":"60","author":"HJ Hunt","year":"2017","unstructured":"Hunt HJ, Belanoff JK, Walters I, Gourdet B, Thomas J, Barton N, Unitt J, Phillips T, Swift D, Eaton E (2017) Identification of the clinical candidate (r)-(1-(4-fluorophenyl)-6-((1-methyl-1\u00a0h-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-hexah ydro-1\u00a0h-pyrazolo[3,4-g]isoquinolin-4a-yl)(4-(trifluoromethyl)pyridin-2-yl)methano ne (cort125134): a selective glucocorticoid receptor (gr) antagonist. J Med Chem 60:3405\u20133421","journal-title":"J Med Chem"}],"container-title":["Archives of Gynecology and Obstetrics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00404-018-4928-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-018-4928-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-018-4928-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,12]],"date-time":"2020-11-12T16:39:12Z","timestamp":1605199152000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00404-018-4928-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,10]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["4928"],"URL":"https:\/\/doi.org\/10.1007\/s00404-018-4928-9","relation":{},"ISSN":["0932-0067","1432-0711"],"issn-type":[{"value":"0932-0067","type":"print"},{"value":"1432-0711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,10]]},"assertion":[{"value":"18 June 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The study was approved by the ethics committee of the Ludwig-Maximilians University Munich (reference number 259-16). Patient data were anonymized.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}